FGF23 and Cause-Specific Mortality in Community-Living Individuals-The Health, Aging, and Body Composition Study
- 1 March 2021
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (3), 711-717
- https://doi.org/10.1111/jgs.16910
Abstract
Objectives Fibroblast growth factor (FGF)-23 is a key regulator of mineral metabolism and has been linked with left ventricular hypertrophy in animal models. Most existing epidemiologic studies evaluated a C-terminal FGF23 assay which measures both the intact (active) hormone and inactive fragments. The relationship of intact FGF23 with cause-specific mortality is unknown. Design Prospective analyses of data from Health, Aging, & Body Composition (HABC) study. Setting Community-living adults aged 70 to 79 years with longitudinal follow up.Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK110427)
- National Institute on Aging (R01AG027002)
This publication has 27 references indexed in Scilit:
- Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs)BMC Nephrology, 2013
- Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the communityKidney International, 2013
- Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals: CHS (Cardiovascular Health Study)Journal of the American College of Cardiology, 2012
- Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy HumansJournal of Clinical Endocrinology & Metabolism, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and MortalityJournal of the American Society of Nephrology, 2011
- Association of Markers of Iron Stores with Outcomes in Patients with Nondialysis-Dependent Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisThe New England Journal of Medicine, 2008
- Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKDAmerican Journal of Kidney Diseases, 2008
- Renal Function and Heart Failure Risk in Older Black and White IndividualsArchives of Internal Medicine, 2006